{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:29:39Z","timestamp":1793942979370,"version":"4.8.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.radonc.2026.111791","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:43:36Z","timestamp":1790135016000},"page":"111791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["LINACS: a living systematic review of the safety of concurrent stereotactic radiotherapy and novel systemic therapies by the ESTRO\/EORTC OligoCare Consortium"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-4932","authenticated-orcid":false,"given":"Nora","family":"Sundahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-0553","authenticated-orcid":false,"given":"Esm\u00e9e Lauren","family":"Looman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4270-5370","authenticated-orcid":false,"given":"Luc","family":"Ollivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3566-5179","authenticated-orcid":false,"given":"Matteo","family":"Bagnalasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2203-4848","authenticated-orcid":false,"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-9071","authenticated-orcid":false,"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1092-7021","authenticated-orcid":false,"given":"Jeffrey","family":"Ryckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4390-1522","authenticated-orcid":false,"given":"Matthew","family":"Culbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida","family":"Bekkering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4412-1450","authenticated-orcid":false,"given":"Sabrina","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111791_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102830","article-title":"Combination of radiotherapy and immunotherapy for brain metastases: a systematic review and meta-analysis","volume":"144","author":"Petrelli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2026.111791_b0010","unstructured":"Geng Y, Zhang Q, Feng S, et al. Safety and Efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis."},{"key":"10.1016\/j.radonc.2026.111791_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2026.111791_b0020","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.627574","article-title":"An open access database of licensed cancer drugs","volume":"12","author":"Pantziarka","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.radonc.2026.111791_b0030","doi-asserted-by":"crossref","unstructured":"Kroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev. Feb 2017;53:25\u201337. doi:10.1016\/j.ctrv.2016.11.013.","DOI":"10.1016\/j.ctrv.2016.11.013"},{"key":"10.1016\/j.radonc.2026.111791_b0035","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recomm***endations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111791_b0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0050","doi-asserted-by":"crossref","unstructured":"De Wolf K, Rottey S, Vermaelen K, et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat Oncol. Sep 22 2017;12(1):157. doi:10.1186\/s13014-017-0893-x.","DOI":"10.1186\/s13014-017-0893-x"},{"key":"10.1016\/j.radonc.2026.111791_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000535","article-title":"Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study","volume":"4","author":"Dengina","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2026.111791_b0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","article-title":"The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group","volume":"38","author":"Franzese","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2026.111791_b0065","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1007\/s00432-022-04352-z","article-title":"The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma","volume":"149","author":"Franzese","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0070","doi-asserted-by":"crossref","unstructured":"Gebbia V, Girlando A, A DIG, et al. Stereotactic radiotherapy for the treatment of patients with oligo-progressive metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitor: data from the real world. Anticancer Res. 2020;40(12):7037\u20137043. doi:10.21873\/anticanres.14730.","DOI":"10.21873\/anticanres.14730"},{"key":"10.1016\/j.radonc.2026.111791_b0075","article-title":"Stereotactic body radiation therapy and concurrent targeted therapy for lung metastases in pediatric sarcoma","volume":"9","author":"Goldsmith","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2017.01.018","article-title":"Phase I trial of radiation therapy and sorafenib in unresectable liver metastases","volume":"123","author":"Goody","year":"2017","journal-title":"Radiother Oncol: J Eur Soc Therapeutic Radiol Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0085","doi-asserted-by":"crossref","unstructured":"Guan Y, Li J, Gong X, et al. Safety and efficacy of hypofractionated stereotactic radiotherapy with anlotinib targeted therapy for glioblastoma at the first recurrence: a preliminary report. Brain Sci. Apr 2 2022;12(4)doi:10.3390\/brainsci12040471.","DOI":"10.3390\/brainsci12040471"},{"key":"10.1016\/j.radonc.2026.111791_b0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0000000000000622","article-title":"Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"43","author":"He","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0095","doi-asserted-by":"crossref","unstructured":"Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiat Oncol. Jun 12 2023;18(1):101. doi:10.1186\/s13014-023-02270-z.","DOI":"10.1186\/s13014-023-02270-z"},{"key":"10.1016\/j.radonc.2026.111791_b0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","article-title":"Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial","volume":"9","author":"Kao","year":"2014","journal-title":"Target Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ijrobp.2024.10.022","article-title":"Phase 2 trial of consolidative stereotactic body radiation therapy in patients with metastatic oncogene-driven non-small cell lung carcinoma treated with tyrosine kinase inhibitors","volume":"121","author":"Keane","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euo.2022.10.004","article-title":"Real-world Practice patterns and safety of concurrent radiotherapy and cabozantinib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium","volume":"6","author":"Loo Gan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0115","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3171\/2016.4.SPINE16229","article-title":"Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma","volume":"25","author":"Miller","year":"2016","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.radonc.2026.111791_b0120","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2026.111791_b0125","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2025.966","article-title":"Safety and efficacy of combining metastasis-directed stereotactic ablative radiation therapy with tyrosine kinase inhibitors versus immune checkpoint inhibitors in metastatic hepatocellular carcinoma","author":"Yang","year":"2026","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111791_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.53809","article-title":"Adverse events after metastases-directed stereotactic radiotherapy and biological cancer therapy","volume":"9","author":"Looman","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2026.111791_b0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3340\/jkns.2015.58.3.205","article-title":"Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer","volume":"58","author":"Kim","year":"2015","journal-title":"Journal of Korean Neurosurgical Society"},{"key":"10.1016\/j.radonc.2026.111791_b0140","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","article-title":"A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation therapy oncology group 0320","volume":"85","author":"Sperduto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2018.03.013","article-title":"Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: a retrospective analysis of 133 consecutive patients","volume":"119","author":"Yomo","year":"2018","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.radonc.2026.111791_b0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-014-1685-x","article-title":"LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases","volume":"122","author":"Ahmed","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CMR.0000000000000250","article-title":"Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.radonc.2026.111791_b0160","doi-asserted-by":"crossref","unstructured":"Durante S, Cuccia F, Rigo M, et al. Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi). Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc. 2024;doi:10.1136\/ijgc-2024-005361.","DOI":"10.1136\/ijgc-2024-005361"},{"key":"10.1016\/j.radonc.2026.111791_b0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-020-01730-0","article-title":"Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database","volume":"16","author":"Kroeze","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0170","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijrobp.2024.09.010","article-title":"Stereotactic body radiation therapy for oligoprogressive ovarian cancer patients treated during poly(ADP-ribose)-polymerase inhibitor maintenance: efficacy and adverse events from the epimetheo retrospective study","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0175","article-title":"Local therapy for isolated central nervous system progression among patients receiving antibody-drug conjugate therapy","volume":"10","author":"Lebow","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0180","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1158\/1078-0432.CCR-18-2851","article-title":"Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4","volume":"25","author":"Stumpf","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2026.111791_b0185","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11060-025-05230-7","article-title":"Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report","volume":"175","author":"Khatri","year":"2025","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0190","doi-asserted-by":"crossref","unstructured":"Ippolito E, Benincasa M, Pantano F, et al. Breast cancer trastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of combart prospective cohort study. The Oncologist. 2025\/09\/01\/ 2025;30(9)doi:10.1093\/oncolo\/oyaf229.","DOI":"10.1093\/oncolo\/oyaf229"},{"key":"10.1016\/j.radonc.2026.111791_b0195","first-page":"06578","article-title":"Multicenter retrospective analysis of the safety and efficacy of sacituzumab govitecan combined with radiation therapy: the French ATTENTION study","volume":"S0360\u20133016","author":"Alati","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2017.11.045","article-title":"Carotid dosimetry and the risk of carotid blowout syndrome after reirradiation with head and neck stereotactic body radiation therapy","volume":"101","author":"Gebhardt","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2013.08.012","article-title":"Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer","volume":"109","author":"Lartigau","year":"2013","journal-title":"Radiother Oncol: J Eur Soc Therapeutic Radiol Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0210","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijrobp.2014.11.023","article-title":"A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck","volume":"91","author":"Vargo","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semradonc.2015.11.007","article-title":"Toxicities following stereotactic ablative radiotherapy treatment of locally-recurrent and previously irradiated head and neck squamous cell carcinoma","volume":"26","author":"Quan","year":"2016","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0220","first-page":"1349","article-title":"Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume","volume":"36","author":"Vargo","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2026.111791_b0225","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.bj.2021.10.013","article-title":"Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer","volume":"45","author":"Huang","year":"2022","journal-title":"Biomed J"},{"key":"10.1016\/j.radonc.2026.111791_b0230","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.radonc.2026.111791_b0235","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fonc.2019.01157","article-title":"Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy","volume":"9","author":"Chiang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0245","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2026.111791_b0250","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/jamaoncol.2024.4085","article-title":"Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma","volume":"10","author":"Chiang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000533425","article-title":"Survival outcome analysis of stereotactic body radiotherapy and immunotherapy (SBRT-IO) versus SBRT-alone in unresectable hepatocellular carcinoma","volume":"13","author":"Chiang","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.radonc.2026.111791_b0260","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70043","article-title":"Safety and efficacy of radiotherapy combined with sintilimab in advanced NSCLC patients who progressed on first or second line therapy: a prospective, multiple center, and single-arm study","volume":"16","author":"Feng","year":"2025","journal-title":"Thoracic cancer"},{"key":"10.1016\/j.radonc.2026.111791_b0265","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1878-0261.13330","article-title":"Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial","volume":"17","author":"Horndalsveen","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0270","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","article-title":"Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer","volume":"13","author":"Hubbeling","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0280","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2023.02.004","article-title":"Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial","volume":"178","author":"Kievit","year":"2023","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.radonc.2026.111791_b0285","doi-asserted-by":"crossref","unstructured":"Korpics MC, Onderdonk BE, Dadey RE, et al. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023;133(10)doi:10.1172\/jci162260.","DOI":"10.1172\/JCI162260"},{"key":"10.1016\/j.radonc.2026.111791_b0290","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bju.15284","article-title":"Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma","volume":"127","author":"Kroeze","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2026.111791_b0295","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111791_b0300","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3340\/jkns.2020.0135","article-title":"Immune checkpoint inhibitors for non-small-cell lung cancer with brain metastasis : the role of gamma knife radiosurgery","volume":"64","author":"Lee","year":"2021","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.radonc.2026.111791_b0305","doi-asserted-by":"crossref","unstructured":"Levy A, Massard C, Soria JC, Deutsch E. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1\/2 trial. European journal of cancer (Oxford, England: 1990). Nov 2016;68:156\u2013162. doi:10.1016\/j.ejca.2016.09.013.","DOI":"10.1016\/j.ejca.2016.09.013"},{"key":"10.1016\/j.radonc.2026.111791_b0310","doi-asserted-by":"crossref","unstructured":"Levy A, Morel D, Texier M, et al. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. Mol Cancer. Mar 23 2024;23(1):61. doi:10.1186\/s12943-024-01970-8.","DOI":"10.1186\/s12943-024-01970-8"},{"key":"10.1016\/j.radonc.2026.111791_b0315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41392-025-02173-3","article-title":"Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results","volume":"10","author":"Levy","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.radonc.2026.111791_b0320","doi-asserted-by":"crossref","unstructured":"Li Z, Liu J, Zhang B, et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nat Commun. 2024;15(1):3260. doi:10.1038\/s41467-024-47420-3.","DOI":"10.1038\/s41467-024-47420-3"},{"key":"10.1016\/j.radonc.2026.111791_b0325","doi-asserted-by":"crossref","unstructured":"Lin J, Guo Q, Guo Z, et al. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent\/metastatic nasopharyngeal carcinoma. Radiat Oncol. 2022;17(1):117. doi:10.1186\/s13014-022-02073-8.","DOI":"10.1186\/s13014-022-02073-8"},{"key":"10.1016\/j.radonc.2026.111791_b0330","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0335","first-page":"e1788","article-title":"Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas","volume":"6","author":"Mahase","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.radonc.2026.111791_b0340","doi-asserted-by":"crossref","unstructured":"Markussen A, Johansen JS, Larsen FO, et al. Nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in patients with metastatic biliary tract cancer: a randomized phase 2 study. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2024;doi:10.1158\/1078-0432.Ccr-24-0286.","DOI":"10.1158\/1078-0432.CCR-24-0286"},{"key":"10.1016\/j.radonc.2026.111791_b0345","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111791_b0350","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cllc.2021.01.012","article-title":"A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer","volume":"22","author":"Mattes","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2026.111791_b0355","doi-asserted-by":"crossref","unstructured":"Minniti G, Anzellini D, Reverberi C, et al. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. J Immunother Cancer. Apr 11 2019;7(1):102. doi:10.1186\/s40425-019-0588-y.","DOI":"10.1186\/s40425-019-0588-y"},{"key":"10.1016\/j.radonc.2026.111791_b0360","doi-asserted-by":"crossref","unstructured":"Minniti G, Lanzetta G, Capone L, et al. Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases. J Immunother Cancer. Dec 2021;9(12)doi:10.1136\/jitc-2021-003730.","DOI":"10.1136\/jitc-2021-003730"},{"key":"10.1016\/j.radonc.2026.111791_b0365","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jjco\/hyy171","article-title":"Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer","volume":"49","author":"Miyamoto","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0370","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/CMR.0000000000000413","article-title":"Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases","volume":"28","author":"Nardin","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.radonc.2026.111791_b0375","doi-asserted-by":"crossref","unstructured":"Ni J, Zhou Y, Wu L, et al. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiat Oncol. Sep 15 2021;16(1):177. doi:10.1186\/s13014-021-01905-3.","DOI":"10.1186\/s13014-021-01905-3"},{"key":"10.1016\/j.radonc.2026.111791_b0380","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/oncolo\/oyad095","article-title":"Hypofractionated stereotactic re-irradiation and anti-PDL1 durvalumab combination in recurrent glioblastoma: STERIMGLI phase I results","volume":"28","author":"Pouessel","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2026.111791_b0385","article-title":"A phase 1 safety study of avelumab plus stereotactic body radiation therapy in malignant pleural mesothelioma","volume":"4","author":"Rimner","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.radonc.2026.111791_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105658","article-title":"Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: a single-center experience","volume":"124","author":"Sari","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0395","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0400","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0405","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111791_b0410","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0415","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ijrobp.2019.03.041","article-title":"Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma","volume":"104","author":"Sundahl","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0420","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111791_b0425","doi-asserted-by":"crossref","unstructured":"Trommer-Nestler M, Marnitz S, Kocher M, et al. Robotic stereotactic radiosurgery in melanoma patients with brain metastases under simultaneous anti-PD-1 treatment. Int J Mol Sci. Sep 7 2018;19(9)doi:10.3390\/ijms19092653.","DOI":"10.3390\/ijms19092653"},{"key":"10.1016\/j.radonc.2026.111791_b0430","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40487-024-00309-z","article-title":"Stereotactic radiotherapy plus nivolumab in patients with locally advanced pancreatic cancer: results from phase 1\/2 clinical CA209-9KH trial","volume":"12","author":"Vo\u0161mik","year":"2024","journal-title":"Oncol Ther"},{"key":"10.1016\/j.radonc.2026.111791_b0435","article-title":"Neoadjuvant programmed cell death protein 1 blockade combined with stereotactic body radiation therapy for stage III(N2) non-small cell lung cancer: a case series","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0440","article-title":"Survival benefits of anti-PD-1 therapy in combination with radiotherapy in chinese melanoma patients with brain metastasis","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0445","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijrobp.2023.03.069","article-title":"Safety and efficacy results from iSABR, a phase 1 study of stereotactic ablative radiotherapy in combination with durvalumab for early-stage medically inoperable non-small cell lung cancer","volume":"117","author":"Wu","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0450","doi-asserted-by":"crossref","unstructured":"Xie C, Duffy AG, Brar G, et al. Correction: immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2021;27(1):358. doi:10.1158\/1078-0432.Ccr-20-4640.","DOI":"10.1158\/1078-0432.CCR-20-4640"},{"key":"10.1016\/j.radonc.2026.111791_b0455","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657024","article-title":"Nivolumab and hypofractionated radiotherapy in patients with advanced lung cancer: ABSCOPAL-1 clinical trial","volume":"11","author":"Ye","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0460","doi-asserted-by":"crossref","unstructured":"Yuce Sari S, Aktas BY, Kertmen N, et al. Does combined fractionated stereotactic radiotherapy and immunotherapy change the outcome of recurrent high-grade gliomas? Cureus. Jun 2021;13(6):e15852. doi:10.7759\/cureus.15852.","DOI":"10.7759\/cureus.15852"},{"key":"10.1016\/j.radonc.2026.111791_b0465","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2024.10.019","article-title":"A randomized multicentre, phase 2 trial of camrelizumab with or without metastasis-directed stereotactic body radiation therapy in recurrent or metastatic nasopharyngeal carcinoma","volume":"121","author":"Zhang","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0470","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-23-0315","article-title":"Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-na\u00efve stage IV PD-L1+ non-small cell lung cancer patients","volume":"29","author":"Zhou","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2026.111791_b0475","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11596-023-2702-0","article-title":"Effect of stereotactic body radiation therapy on diverse organ lesions in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors","volume":"43","author":"Zhu","year":"2023","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.radonc.2026.111791_b0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004680","article-title":"Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: a single-arm, phase 2 trial from China","volume":"22","author":"Chen","year":"2025","journal-title":"PLoS Med"},{"key":"10.1016\/j.radonc.2026.111791_b0485","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3748\/wjg.v29.i24.3871","article-title":"Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a phase II clinical trial","volume":"29","author":"Chen","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.radonc.2026.111791_b0490","doi-asserted-by":"crossref","unstructured":"Deming DA, Kraus SG, Brand J, et al. Tumor matrix proteoglycan accumulation and processing alters T cell effector function and the response to immunotherapy in patients with oligometastatic colorectal cancer. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2026\/02\/11\/ 2026;doi:10.1158\/1078-0432.CCR-25-2780.","DOI":"10.1158\/1078-0432.CCR-25-2780"},{"key":"10.1016\/j.radonc.2026.111791_b0495","article-title":"Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair\/microsatellite unstable metastatic colorectal cancer","volume":"5","author":"Gandini","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0500","doi-asserted-by":"crossref","unstructured":"Giordano A, Graham N, Aizer AA, et al. A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis. Breast Cancer Res Treat. 2026\/03\/07\/ 2026;216(2)doi:10.1007\/s10549-026-07932-6.","DOI":"10.1007\/s10549-026-07932-6"},{"key":"10.1016\/j.radonc.2026.111791_b0505","article-title":"Outcomes and toxicity of concomitant radioimmunotherapy following PD-1 blockade for locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"2025","author":"Kassardjian","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0510","article-title":"The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study","author":"Lee","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2026.111791_b0515","article-title":"Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - a phase II trial (PEMRAD)","volume":"8","author":"O'Kane","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.radonc.2026.111791_b0520","article-title":"Pathologic responses to stereotactic ablative radiotherapy in combination with nivolumab for early stage NSCLC: a phase 2 study","volume":"7","author":"Schvartsman","year":"2026","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.radonc.2026.111791_b0525","first-page":"00004","article-title":"Stereotactic body radiation therapy with pembrolizumab in programmed cell death protein 1 inhibitor-refractory recurrent or metastatic head and neck squamous cell carcinoma: a phase 2 trial","volume":"S0360\u20133016","author":"So","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0530","first-page":"06521","article-title":"Stereotactic body radiation therapy augmented checkpoint inhibitor immunotherapy response in heavily pretreated metastatic osteosarcoma","volume":"S0360\u20133016","author":"Zhu","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0535","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11060-022-03951-7","article-title":"Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases","volume":"157","author":"Abdulhaleem","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0540","article-title":"Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: a nonrandomized, open-label phase 1b study","volume":"6","author":"Ahmed","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0545","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0550","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.ijrobp.2023.11.040","article-title":"Combining dual checkpoint immunotherapy with ablative radiation to all sites of oligometastatic non-small cell lung cancer: toxicity and efficacy results of a phase 1b trial","volume":"118","author":"Bassetti","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0555","article-title":"Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: a retrospective monocentric toxicity analysis","volume":"39","author":"Bodensohn","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0560","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/thy.2022.0050","article-title":"A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer","volume":"32","author":"Lee","year":"2022","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"10.1016\/j.radonc.2026.111791_b0565","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11060-023-04543-9","article-title":"Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery","volume":"166","author":"Tang","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0570","doi-asserted-by":"crossref","unstructured":"Mandal\u00e0 M, Amaral T, Rutkowski P, et al. Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study. Eur J Cancer (Oxford, England : 1990). 2025;225:115567. doi:10.1016\/j.ejca.2025.115567.","DOI":"10.1016\/j.ejca.2025.115567"},{"key":"10.1016\/j.radonc.2026.111791_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105508","volume":"10","author":"Seligmann","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2026.111791_b0580","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/cac2.70051","article-title":"Stereotactic body radiotherapy plus cadonilimab (PD-1\/CTLA-4 bispecific antibody) as third-line or beyond therapy for refractory solid tumors: a phase 1b study","volume":"45","author":"Xiao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.radonc.2026.111791_b0585","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.radonc.2026.111791_b0590","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 Trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0595","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-018-2880-y","article-title":"Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity","volume":"139","author":"Diao","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0600","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0605","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1283461","article-title":"Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab","volume":"6","author":"Skrepnik","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2026.111791_b0610","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ijrobp.2017.11.029","article-title":"Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma","volume":"100","author":"Sundahl","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0615","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11060-021-03782-y","article-title":"Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis","volume":"153","author":"Chen","year":"2021","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0620","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2017.06.2466","article-title":"Multicenter, phase 1, dose escalation study of hypofractionated stereotactic radiation therapy with bevacizumab for recurrent glioblastoma and anaplastic astrocytoma","volume":"99","author":"Clarke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0625","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.rpor.2015.01.004","article-title":"Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas","volume":"20","author":"Conde-Moreno","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2026.111791_b0630","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.wneu.2019.08.233","article-title":"Hypofractionated radiosurgery plus bevacizumab for locally recurrent brain metastasis with previously high-dose irradiation","volume":"133","author":"Guan","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1016\/j.radonc.2026.111791_b0635","doi-asserted-by":"crossref","first-page":"1047.e1","DOI":"10.1016\/j.wneu.2017.07.185","article-title":"Bevacizumab plus radiosurgery for nonsquamous non-small cell lung cancer patients with brain metastases: safe combination?","volume":"107","author":"Guinde","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.radonc.2026.111791_b0640","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11060-014-1488-0","article-title":"A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema","volume":"119","author":"Wang","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107911","article-title":"Efficacy and safety of a \u201csandwich therapy\u201d based on staged stereotactic radiosurgery and bevacizumab for large brainstem metastases","volume":"233","author":"Wang","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.radonc.2026.111791_b0650","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10143-024-02369-1","article-title":"Outcomes of 2-SSRS plus bevacizumab therapy strategy for brainstem metastases (BSM) over 2 cm(3): a multi-center study","volume":"47","author":"Wang","year":"2024","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.radonc.2026.111791_b0655","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11060-015-2019-3","article-title":"Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report","volume":"127","author":"Yomo","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2026.111791_b0660","article-title":"Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis","volume":"2024","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2026.111791_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103189","article-title":"Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial","volume":"82","author":"Zheng","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.radonc.2026.111791_b0670","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10143-025-03907-1","article-title":"Radiosurgery for recurrent high-grade gliomas: a critical analysis based on a retrospective single-center series","volume":"48","author":"Novak Filho","year":"2025","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.radonc.2026.111791_b0675","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/cac2.70078","article-title":"Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053)","volume":"45","author":"Zhou","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.radonc.2026.111791_b0680","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111330","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4\/6, HER2, PARP, or mTOR inhibitors","volume":"215","author":"van Aken","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0690","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2025.09.008","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","volume":"37","author":"van Aken","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0695","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111791_b0700","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0705","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/JTO.0b013e318183aa1f","article-title":"Southwest oncology group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2","volume":"3","author":"Hesketh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0710","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijrobp.2016.01.038","article-title":"Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the eastern cooperative oncology group (ECOG)","volume":"95","author":"Anker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111791_b0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110910","article-title":"ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","volume":"208","author":"van Aken","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111791_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106076","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF\/MEK inhibitors","volume":"11","author":"van Aken","year":"2026","journal-title":"ESMO Open"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:15:22Z","timestamp":1793942122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026006316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":144,"alternative-id":["S0167814026006316"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111791","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LINACS: a living systematic review of the safety of concurrent stereotactic radiotherapy and novel systemic therapies by the ESTRO\/EORTC OligoCare Consortium","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111791"}}